{"filings":[{"id":528636,"accession_number":"0001493152-26-024438","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-05-19T20:54:13+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enovis shareholders approve plan amendment adding 3.65M shares, raising director pay cap to $750k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2020 Omnibus Incentive Plan adding 3,650,000 shares of common stock for issuance.","Outside director annual compensation limit increased from $350,000 to $750,000 (200% in first year).","All ten Board nominees elected; ratification of Ernst & Young as auditor passed; say-on-pay approved.","Plan amendment effective upon stockholder approval at May 19, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92760,"accession_number":"0001420800-26-000017","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q1 net sales up 5% to $589M, net loss $8M; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $589M (+5% reported, +3% organic); Recon sales +11% reported, P&R flat.","Net loss $8M (1.4% of sales), $0.15 per share; adjusted EPS $0.89; adjusted EBITDA $104M (17.6% of sales).","FY2026 guidance reaffirmed: revenue $2.31-2.37B, adjusted EBITDA $425-435M, adjusted EPS $3.52-$3.73.","Company cites solid execution, new product launches, but dynamic macroeconomic environment as factors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":589151000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103865,"accession_number":"0001420800-26-000008","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis posts FY2025 net loss of $1.18B including $1.05B goodwill impairment; Q4 sales $576M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net sales $2.2B, up 7% reported/6% organic; Recon sales +10%, P&R +4%.","Q4 net loss $519M includes $501M non-cash goodwill impairment; adjusted EPS $0.95.","Full-year adjusted EBITDA $403M; adjusted diluted EPS $3.30.","2026 guidance: revenue $2.31-2.37B (4-6% organic growth), adjusted EBITDA $425-435M, adjusted EPS $3.52-3.73.","CEO cites operational progress, Lima integration, and debt reduction; outlook reflects cautious macro view."],"consensus_eps_estimate":null,"consensus_eps_actual":-20.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2248049000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103864,"accession_number":"0001493152-26-001206","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis to present at J.P. Morgan Healthcare Conference; presentation materials furnished, no specific updates disclosed.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Management will present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.","Presentation materials attached as Exhibit 99.1, but exhibit text not provided for detailed analysis.","No new financial or operational information disclosed; routine investor event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120137,"accession_number":"0001493152-25-027738","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enovis CHRO Patricia Lang to retire; Laura Singleton appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patricia Lang will step down as SVP & CHRO effective April 3, 2026, transitioning to advisory role until April 3, 2027.","Laura Singleton, currently VP of HR for Reconstructive segment, to become SVP & CHRO on April 3, 2026.","Singleton joined Enovis in Feb 2019 via DJO Global acquisition; prior HR roles at Toppan Photomasks, Ixia, Millennium Labs.","Lang will receive current base salary for 6 months of advisory period, then reduced up to 50% through April 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120136,"accession_number":"0001493152-25-027007","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Enovis amends credit agreement; extends maturity to 2030, upsizes cash offset to $400M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended credit agreement provides $1.1B revolver and $700M term loan, both maturing Dec 8, 2030.","Repaid ~$335M of revolver with term loan proceeds; outstanding as of Dec 8: $167M revolver, $700M term loan.","Maximum cash offset for leverage calculations increased from $150M to $400M; acquisition consideration limit raised to $200M.","Covenant: temporary leverage increase available for acquisitions ≥$300M (previously $500M); new lenders added.","Applicable margin reduced for total leverage ratio below 1.50x; maturity conditional on liquidity vs. convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120135,"accession_number":"0001493152-25-023418","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enovis EVP Strategy & Business Dev Pryor steps down; advisory role through Mar 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel A. Pryor departed as EVP Strategy and Business Development on Nov 7, 2025; position eliminated.","Pryor remains an employee in advisory role through March 31, 2026 for transition services.","Separation agreement: continues base salary, benefits, 2025 bonus eligibility, and equity vesting through departure.","Post-departure severance: base salary plus larger of target bonus or avg of top two bonuses from prior 3 years.","Also receives 12-month health coverage continuation and outplacement assistance capped at $75,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120134,"accession_number":"0001420800-25-000038","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q3 sales up 9% to $549M; raises FY adjusted EBITDA and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $549M (+9% reported, +7% organic); Recon +12% reported, P&R +6% reported.","Net loss $571M including $548M non-cash goodwill impairment; adjusted EPS $0.75.","Divested Dr. Comfort (Diabetic Footcare) unit in Oct for up to $60M.","Raised FY2025 guidance: revenue $2.24-2.27B, adj. EBITDA $395-405M, adj. EPS $3.10-3.25."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":1672291000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136709,"accession_number":"0001420800-25-000029","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q2 revenue up 7%, guided FY25 higher; adjusted EPS $0.79","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $565M (+7% reported, +5% organic); Recon +11%, P&R +5%.","Net loss $37M ($0.64 loss/share); adjusted EBITDA $97M (17.2% of sales).","Adjusted diluted EPS $0.79; full-year adjusted EPS guidance raised to $3.05-3.20.","FY25 revenue outlook raised to $2.245-2.275B; adjusted EBITDA $392-402M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123379000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153927,"accession_number":"0001193125-25-123977","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Enovis shareholders elect nine directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; For votes ranged from 49.6M to 50.4M shares (broker non-votes 1.7M each).","Ratification of Ernst & Young as independent auditor for FY2025: 51.6M For, 0.5M Against, 43K Abstain.","Non-binding advisory vote on executive compensation approved: 49.6M For, 0.9M Against, 48K Abstain (1.7M broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153926,"accession_number":"0001420800-25-000015","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q1 revenue +8% to $559M; adjusted EBITDA margin 17.7% (+160bps); appoints Damien McDonald CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $559M, +8% reported; Recon +11%, P&R +5% YoY.","Net loss from cont. ops $56M ($0.98 loss per share); adjusted EPS $0.81.","Adjusted EBITDA $99M (17.7% of sales, +160 bps vs Q1 2024).","Raised FY2025 rev guidance to $2.22-2.25B; lowered adj. EBITDA to $385-395M (incl. $20M tariff impact).","Appointed Damien McDonald as CEO effective May 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":558834000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153925,"accession_number":"0001193125-25-070882","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Enovis appoints Damien McDonald as CEO effective May 12; Q1 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Damien McDonald, former LivaNova CEO, appointed CEO effective May 12, 2025; succeeds retiring CEO Matt Trerotola.","Matt Trerotola will not stand for re-election; Sharon Wienbar named independent Chair of the Board.","McDonald receives $1M base salary, 125% target bonus, and $6.5M initial equity award (50% time-based, 50% performance-based).","Q1 2025 guidance reiterated: revenue $555-563M, adjusted EBITDA $97-100M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172578,"accession_number":"0001193125-25-054845","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enovis CEO Trerotola signs retirement transition; will serve as Special Advisor for 1 year post-successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Matthew Trerotola's retirement effective when successor appointed; transition agreement signed March 13, 2025.","He will serve as Special Advisor for one year after Appointment Date, receiving current $1,077,000 base salary for two months then reduced (min 50%).","No further equity or long-term incentive awards; outstanding awards continue per retirement provisions in equity agreements.","Non-compete applies for two years after Retirement Date in orthopedic and medical device business; non-solicitation and non-disparagement also in place.","Successor CEO has not yet been named by the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172577,"accession_number":"0001420800-25-000007","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q4 net loss $704M on $645M goodwill impairment; CEO plans retirement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $561M (+23% reported, +6% comparable); Recon sales +59% reported.","Adjusted EBITDA $113M (20% of sales), +210 bps YoY; adj EPS $0.98 vs reported loss $12.06.","Full-year revenue $2.1B (+23% reported); adj EBITDA $377M (18% of sales).","2025 guidance: revenue $2.19-2.22B, adj EBITDA $405-415M, adj EPS $3.10-$3.25.","CEO Matt Trerotola to retire upon appointment of successor; board to lead search."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":2107623000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172576,"accession_number":"0001193125-25-035746","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Enovis CEO Matt Trerotola to retire; board begins search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Trerotola retiring upon successor appointment; will serve as Executive Advisor for one year.","Board engaged executive search firm to identify growth-oriented med-tech leader for CEO role.","Trerotola to address transition during Q4/FY2024 earnings call scheduled later today.","No successor named; transition planned as part of succession process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172575,"accession_number":"0001193125-25-013860","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enovis files prospectus supplement to register 971,343 shares for resale by Emil","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Second tranche of 971,343 shares issued to Emil on Jan 15, 2025 as part of Lima acquisition consideration.","Shares registered for resale under the registration rights agreement; no new issuance or dilution.","Legal opinion from Latham & Watkins regarding legality of the securities attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172574,"accession_number":"0001193125-25-004929","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enovis to present at J.P. Morgan Healthcare Conference on Jan 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Matt Trerotola and CFO Ben Berry present at the conference at 9:45 AM PST.","Live webcast and replay available at www.enovis.com; presentation materials in Exhibit 99.1.","No specific operational or financial updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189567,"accession_number":"0001420800-24-000026","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q3 net sales $505M (+21% reported), adj. EPS $0.73 beat; raises FY adj. EPS guidance to $2.75-2.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net sales $505M, up 21% reported/6% comparable; Recon sales +57% reported/9% comparable.","Net loss from continuing ops $0.61/sh; adjusted EPS $0.73, up 30% YoY.","Adjusted EBITDA $90M (17.9% of sales), margin +220 bps vs prior year.","FY2024 guidance: revenue ~$2.10B; adj. EBITDA $373-378M; adj. EPS raised from $2.62-2.77 to $2.75-2.80.","Lima acquisition contributed to Recon growth; integration progress cited."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":1546648000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206072,"accession_number":"0001420800-24-000019","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q2 sales up 23% to $525M; raises adjusted EPS guidance to $2.62-$2.77","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $525M (+23% reported, +5% comparable); Recon sales +60% reported.","Reported net loss from cont ops $0.34/sh; adjusted EPS $0.62; adj EBITDA $90M (17.2% of sales, +190bps).","Raised FY2024 adj EPS guidance to $2.62-$2.77 (from $2.52-$2.67); revenue narrowed to $2.08-$2.13B.","Received FDA 510k clearance for Arvis 2.0 Shoulder and Altivate Reverse Glenoid; launches expected Q3 2024.","Opened new manufacturing facility in San Daniele and Business Technology Center in Lisbon."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1041426000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206071,"accession_number":"0001193125-24-181063","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enovis files resale registration for 971,343 shares issued to former Lima shareholder","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement for resale of 971,343 shares of common stock held by Emil Holding II.","Shares issued on July 16, 2024 as first tranche of consideration for LimaCorporate acquisition.","Second tranche of up to 971,343 shares expected to be issued in Q1 2025, subject to conditions.","Registration covers only the first tranche; no change to business operations or financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223102,"accession_number":"0001193125-24-144942","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Enovis stockholders approve 2.1M share increase to incentive plan and officer exculpation charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment adding 2,100,000 shares to the 2020 Omnibus Incentive Plan for future awards.","Charter amendment to permit officer exculpation under DGCL approved; filed with Delaware Secretary of State on May 22, 2024.","All 10 director nominees elected, including Matthew L. Trerotola and Barbara W. Bodem, with voting results provided.","Ratified Ernst & Young as independent auditor for FY2024 and approved advisory say-on-pay proposal.","Charter amendment passed with 42.3M for, 4.8M against; plan amendment passed with 45.6M for, 1.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223101,"accession_number":"0001420800-24-000009","cik":1420800,"company_name":"Enovis CORP","ticker":"ENOV","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enovis Q1 revenue $516M (+27% YoY), adjusted EPS $0.50, raises full-year outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $516M, up 27% reported and 5% proforma YoY; Recon sales +66% reported, +7% proforma.","GAAP net loss from continuing ops $72M ($1.32/share loss); adjusted EPS of $0.50.","Adjusted EBITDA $83M (16.1% of sales), margin expanded 220 bps YoY.","Updated FY2024 guidance: revenue $2.06-2.16B, adj EBITDA $368-383M, adj EPS $2.52-$2.67.","Closed LimaCorporate acquisition; launched Arvis 2.0 and other products at AAOS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":516266000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1327105846.7524881,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}